Arcturus sold 2,466,395 shares to Meiji for $50.0 million at an 80% premium, alongside an ARCT-154 license and a nonbinding MOU covering pandemic preparedness in Japan.
ARCT · Arcturus Therapeutics Holdings Inc.
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
Key stats
- Short volume, last session
- 55%
- Last earnings
- Nov 5, 2026
- Latest filing
- 10-Q · Nov 5
- Price history
- Jan 2020 to Nov 2026
Up next
Latest documents
Arcturus Therapeutics has guided a full data presentation for the complete fourth cohort of Phase 2 cystic fibrosis data for the second quarter in 27, with enrollment completing by year-end. A Phase 3 decision would trigger a $40 million contribution from Thermo Fisher. For its liver program, ARCT-2601 is expected to start its trial early next year, with top-line data in the second half of 27.
Arcturus plans Phase 2 dosing of ARCT2601 next quarter and expects top-line data in the second half of 2027. ARCT032 Phase 2 enrollment is expected by year-end, with full data planned for the second quarter of 2027.
Arcturus Therapeutics Holdings Inc. recognized approximately $16.8 million of revenue after terminating its CSL Seqirus collaboration, regaining KOSTAIVE and other vaccine programs. Nine-month revenue fell $51.5 million, while cash and cash equivalents were $184.8 million at September 30, 2026.
Arcturus reported a net loss of $7.4 million for the three months ended September 30, 2026, compared with $13.4 million a year earlier, after recognizing the $12.0 million termination payment from CSL Seqirus. Cash and cash equivalents were $184.8 million at September 30, 2026. The company plans ARCT-032 Phase 2 data presentation in Q2 2027.
Metrics snapshot
Useful current figures from the complete screener profile.
Quarterly results
* Q4 derived as the full year minus Q1 to Q3.
AI Brief
Q3 FY26 earnings call · Nov 5, 2026TL;DR. Arcturus reported meaningful biomarker activity and tolerability in ARCT-810, 38-fold greater LUNAR 2.0 potency in primates, ARCT-2601 development milestones, accelerated ARCT-032 enrollment and a cash runway through 2028. The quarter also featured lower nine-month revenue, a larger nine-month net loss, declining cash and uncertainty over a late-December study start.
- + ARCT-810 demonstrated meaningful biomarker activity and was generally safe and well tolerated in Phase 2.
- + ARCT-032 Phase 2 enrollment accelerated following additional clinical-site activations in Israel and Turkey.
- + LUNAR 2.0 demonstrated 38-fold greater potency in a non-human primate study.
- + ARCT-2601 Phase 2 dosing is planned for Q1 2027, with top-line data expected in H2 2027.
- + A decision to advance ARCT-032 into Phase 3 triggers significant Thermo Fisher contributions.
- + The company has a cash runway of over two years through year-end 2028.
- − Cash and cash equivalents declined $46.1 million during the first nine months of 2026.
- − Nine-month revenue was $23.3 million versus $74.8 million in the prior-year period.
- − Nine-month net loss was $58.2 million versus $36.7 million in the prior-year period.
- − A study start by late December was described as speculative.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders SellIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
ARCT
this stock
Arcturus Therapeutics Holdings Inc.
|
$214.73M | +21.5% | -46.1% | — | 18.8% |
|
VRTX
Vertex Pharmaceuticals Inc
|
$130.58B | +13.6% | +46.2% | 33.2 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$95.24B | +19.3% | +20.8% | 20.4 | 2.1% |
|
MRNA
Moderna, Inc.
|
$78.90B | +561.2% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$62.17B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| ARCT | -10.9% | -24.3% | -2.6% | -32.5% | +21.5% |
| SPY | -8.6% | -9.2% | -9.2% | -8.7% | +1.2% |
| vs SPY | -2.3% | -15.1% | +6.6% | -23.7% | +20.4% |